Sarepta Therapeutics (SRPT) volatility pulls back on sharp rally on FDA approval

Sarepta Therapeutics (NASDAQ: SRPT) is recently up $2.05 to $50.99 in the premarket after saying it sees the U.S. annual cost of eteplirsen at $300,000, a day after rallying 73% on the FDA approval of eteplirsen. September weekly call option implied volatility is at 145, October is at 88; compared to its 52-week range of 79 to 399.

You May Also Be Interested In

• Netflix (NFLX) call put ratio 2.2 calls to 1 put into quarter results
• Cytokinetics (CYTK) July 100 and January 80 calls active, share price down 3.9%
• Vaxcyte, Inc (PCVX) call put ratio 1.6 calls to 1 put as share price down 2.4%